Skip to content

Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02931747
Enrollment
75
Registered
2016-10-13
Start date
2016-07-31
Completion date
2017-03-31
Last updated
2017-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Bacopa Monnieri, Working memory, Cognitive processing, Student

Brief summary

The purpose of this study is to determine the effect of Bacopa Monnieri on working memory and cognitive processing in student.

Detailed description

Learning and working memory are two of the key role for studying and work successful for student particular the high school student who study hard and preparing themselves for the graduate study. The consumption of brain booster product or functional food for improving memory has gained much attention. It has been reported that Bacopa Monnieri could improve learning and working memory in elderly subject by improving the N100 and P300 event related potential. Therefore, Bacopa Monnieri might be the potential product for improving the learning and working memory in student particular high school student.

Interventions

DIETARY_SUPPLEMENTPlacebo

Subjects are received Placebo once daily for 16 weeks.

DIETARY_SUPPLEMENTBacopa Monnieri 300 mg/day

Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.

DIETARY_SUPPLEMENTBacopa Monnieri 600 mg/day

Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.

Sponsors

Government Pharmaceutical Organization
CollaboratorUNKNOWN
Khon Kaen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy student subject aged between 15-18 years old who studying in the school within Khon Kaen province. * Body mass index is between 18.5-24.9

Exclusion criteria

* Subjects who are diagnosed with one of the following: cardiovascular diseases, respiratory disease, neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded. * Subjects who take any medicine or nutraceuticals or hormone that effect on central nervous system are excluded. * Alcohol addict or smoking addiction (more than 10 pieces/day) * Athlete or subjects who have a regular exercise more than 3 times/week * Subjects who don't follow the instruction during the trial * Subjects who are participating the other project.

Design outcomes

Primary

MeasureTime frameDescription
Cognitive processing using the latency of P300 wave4 monthsThe latency of P300 wave was measured and expressed as millisecond.
Cognitive processing using the amplitude of P300 wave4 monthsThe amplitude of P300 wave was measured and expressed as micro-volt.
Attention using the latency of N100 wave4 monthsThe latency of N100 wave was measured and expressed as millisecond.
Attention using the amplitude of N100 wave4 monthsThe amplitude of N100 wave was measured and expressed as micro-volt.

Secondary

MeasureTime frameDescription
Activity of superoxide dismutase in serum4 month
Activity of catalase in serum4 month
Activity of glutathione peroxidase in serum4 month
Consumption safety of Bacopa Monnieri using electrocardiogram (EKG)4 month
Accuracy of working memory using computerized battery test4 monthsThe accuracy of working memory was determined and expressed as percentage.
Speed of working memory using computerized battery test4 monthsThe speed of working memory was determined and expressed as millisecond.
Monoamine oxidase activity in serum4 months
Assessment of mood scale using Bond-Lader visual analogue scales4 months
Acetylcholinesterase activity in serum4 months
Consumption safety of Bacopa Monnieri using hematological values .4 monthThe hematological values including red blood cell, white blood cell, hematocrit and platelet were determined and the data was expressed as number of subject presented with abnormal hematological value.
Consumption safety of Bacopa Monnieri using blood chemistry4 monthThe blood chemistry values including renal function test, liver function test, lipid profile, electrolytes and glucose were determined and the data was expressed as number of subject presented with abnormal blood chemistry value.
Consumption safety of Bacopa Monnieri using blood pressure measurement4 month
Assessment of psychiatric symptoms using the symptom check list 90 (SCL-90)4 months
Glutamic acid decarboxylase (GAD) activity in serum4 months
Gamma-aminobutyric acid (GABA)-transaminase in serum4 months
Malondialdehyde level in serum4 months

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026